Squamous cell carcinoma of lung

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase I/II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I/II

1 trial
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting

Phase I

2 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2022-501570-18-00 3 countries 2023 n=145
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505858-18-00 4 countries 2024 n=175
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 0
BioNTech SE Commercial 1 Phase I/II 1
New trials by year
2023
1
2024
1
2026
1
← All indication landscapes